A deep dive into Biocon Ltd. (BIOCON) — examining the financials, valuation picture, and who owns the stock.
Biocon Revenue Trend
For FY2025, Biocon Ltd. recorded revenue of ₹16,470 Cr. That's 5.4% higher than the ₹15,621 Cr it brought in during FY2024.
On a 10-year view, revenue grew from ₹3,090 Cr to ₹16,470 Cr at a 18.2% CAGR. That kind of compounding is what separates the growth names.
A ₹16,470 Cr revenue base makes Biocon Ltd. a major name in the Indian pharmaceuticals sector.
Biocon Ltd. has posted revenue growth for 10 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹16,470 Cr | +5.4% |
| FY2024 | ₹15,621 Cr | +39.8% |
| FY2023 | ₹11,174 Cr | +36.5% |
| FY2022 | ₹8,184 Cr | +11.2% |
| FY2021 | ₹7,360 Cr | — |
View Biocon Ltd.'s full 10-year revenue trend with CAGR analysis →
Biocon Profitability
At ₹1,429 Cr, Biocon Ltd.'s FY2025 net profit was 10.1% ahead of FY2024.
On the margin front, things were flat — net profit margin stayed around 8.7% in FY2025.
The diluted EPS figure moved down to ₹8.46 in FY2025, against ₹8.54 posted in FY2024.
Is Biocon Undervalued
The P/E Ratio valuation pegs Biocon Ltd.'s fair value at ₹416, which is 0.8% upside from the current price.
Biocon Ltd. shares are currently trading at ₹412.45.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹416 | 0.8% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Biocon Ltd. with detailed assumptions →
Biocon Shareholding Pattern
The promoter group reduced its holding to 54.5% from 60.6%.
FII holding stands at 7.4%, up from 5.7% in the year-ago quarter.
DII ownership is at 21.7%, up from the 15.7% recorded a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Dec 2025 | 54.5% | 7.4% | 21.7% | 16.3% |
| Sep 2025 | 54.5% | 6.6% | 22.1% | 16.7% |
| Jun 2025 | 54.5% | 6.0% | 22.8% | 16.5% |
| Mar 2025 | 60.6% | 5.7% | 15.7% | 17.8% |
Track quarterly shareholding changes for Biocon Ltd. →
Biocon Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹587.97B at the end of FY2025, up 4.9% from ₹560.71B a year earlier.
Intangibles & Goodwill is the largest block at 46.0%, followed by Property, Plant & Equipment at 21.8% and Receivables at 9.3%.
Equity makes up 47.1% of liabilities and equity, with debt at 31.2% and operating liabilities at 21.6%. Over the year, debt is up 12.8% and equity is up 9.6%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 36.74B |
| Receivables | 54.88B |
| Inventories | 49.31B |
| Property, Plant & Equipment | 128.10B |
| Investments | 8.67B |
| Intangibles & Goodwill | 270.58B |
| Other Assets | 39.69B |
| Category | Value |
|---|---|
| Equity | 277.13B |
| Short-term Debt | 54.18B |
| Long-term Debt | 129.45B |
| Trade Payables | 65.49B |
| Other Liabilities | 61.74B |
Biocon Key Takeaways
Here's the bottom line on Biocon Ltd. (BIOCON) based on the latest available financials.
Revenue of ₹16,470 Cr in FY2025, up 5.4% year-over-year.
Long-term revenue has been compounding at 18.2% annually over 10 years.
The company is profitable, with a net margin of 8.7% and net income of ₹1,429 Cr.
The P/E Ratio model implies 0.8% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Biocon Ltd..